Treatment for CMV Colitis
The treatment of choice for CMV colitis is intravenous ganciclovir 5 mg/kg twice daily for 3-5 days, followed by oral valganciclovir 900 mg twice daily for a total duration of 2-3 weeks. 1, 2
Antiviral Therapy Regimen
The standard treatment protocol is well-established across multiple high-quality guidelines:
- Initial phase: IV ganciclovir 5 mg/kg every 12 hours for 3-5 days
- Transition phase: Switch to oral valganciclovir 900 mg twice daily once clinical improvement occurs
- Total duration: Complete 2-3 weeks of therapy (combining IV and oral phases) 1, 3, 2
The 2025 British Society of Gastroenterology guidelines 1 and 2021 ECCO guidelines 2 both strongly support this regimen. Earlier transition to oral therapy is acceptable based on treatment response 2.
Management of Immunosuppression
A critical decision point involves managing concurrent immunosuppressive therapy:
- Corticosteroids should be tapered rather than abruptly discontinued 2
- Consider withholding or temporarily discontinuing other immunosuppressants (particularly thiopurines) during active CMV treatment 4, 2
- In severe disseminated CMV infection, discontinuation of all immunosuppressive therapy is mandatory 2
The evidence shows that many patients can maintain immunosuppression during CMV treatment, particularly when viral load is low 2. However, this remains controversial—some studies suggest immunosuppressant discontinuation plus antivirals achieves similar outcomes to standard rescue therapy 2.
Context-Specific Considerations
In Inflammatory Bowel Disease (IBD)
When CMV colitis occurs in the setting of acute severe ulcerative colitis or steroid-refractory disease:
- Perform flexible sigmoidoscopy with biopsies for urgent histology including specific CMV assessment 4, 1
- Diagnosis requires tissue biopsy with immunohistochemistry (IHC)—this is the gold standard 5, 3, 5
- Consult virology regarding ongoing immunosuppressive therapies 4, 1
- Recent evidence suggests adequate antiviral therapy (≥14 days) significantly reduces complications in IBD patients with CMV colitis 6
In Immunocompromised Patients
For severely immunocompromised patients (transplant recipients, HIV, hematology-oncology):
- Adults: IV ganciclovir 5 mg/kg twice daily for 3-5 days, then oral valganciclovir 900 mg twice daily for remainder of 2-3 week course 5
- Pediatric patients: 14-21 days of parenteral ganciclovir is recommended; early switch to oral therapy may promote CMV reactivation 5
- Broad-spectrum antibiotic therapy is indicated 5
Alternative Agents
For ganciclovir-intolerant patients or ganciclovir-resistant CMV:
- Foscarnet is the primary alternative 2
- Requires strict monitoring of renal function and electrolytes
- Concomitant normal saline administration reduces risk of irreversible renal damage 2
Maribavir has emerged as an option for resistant/refractory CMV in transplant settings, though it has poor CNS and ocular penetration 7.
Surgical Intervention
Subtotal or partial colectomy is indicated when:
- Toxic megacolon develops
- Fulminant colitis occurs
- Perforation is present
- Ischemia develops 5
No definitive data exist on superiority of segmental versus subtotal colonic resection 5.
Critical Pitfalls to Avoid
Do not rely on blood serology for diagnosis—CMV seroprevalence is ≥70% in adults, making serology diagnostically useless 5
Do not delay antiviral therapy while awaiting confirmatory testing in severely ill patients with high clinical suspicion 1
Monitor for ganciclovir toxicity: neutropenia and thrombocytopenia are common and can complicate management, requiring multidisciplinary involvement with infectious disease specialists 2
Recognize that untreated CMV disease in immunodeficient patients carries high mortality—up to 70% in-hospital mortality in severely ill immunocompetent patients, with worse outcomes in immunocompromised patients 5
In IBD patients, CMV colitis increases colectomy risk up to 7-fold and significantly worsens mortality 5
The evidence consistently supports prompt antiviral therapy with the ganciclovir/valganciclovir regimen, with careful attention to immunosuppression management and early infectious disease consultation in complex cases.